Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Data Shows Requip-Modutab Improves Nocturnal Symptoms In Patients With Advanced Parkinson's Disease
New data presented at the 13th International Congress of Parkinson"s Disease and Movement Disorders show that Requip-Modutab* (ropinirole prolonged release tablets) improves nocturnal symptoms experienced by patients with advanced Parkinson"s disease (PD).[i] The data showed that patients with more significant nocturnal symptoms had a greater improvement with Requip-Modutab, when used as an adjunct to levodopa (L-dopa), versus placebo. These data indicate that once-daily Requip-Modutab remains effective in treating PD symptoms over the night as well as during the day and provides benefit to those in most need. Sleep disturbances, a key element of nocturnal symptoms, are one of the most common non-motor complications of PD and can affect up to 98% of patients.[ii]
generic viagra online
HANYS Presents Its Top Honor, The Distinguished Service Award, To New York State's Health Care Auxilians
Hundreds of health care leaders from throughout the state gathered Wednesday evening in Lake George as the Healthcare Association of New York State (HANYS) presented its 30th annual Distinguished Service Award, its highest honor, to New York State"s health care auxiliaries. Since 1979, HANYS has awarded the Distinguished Service Award to individuals who demonstrate their extraordinary commitment to improving health care through service to their community.
News of the day
A Step Closer To Drugs Against Winter Vomiting Disease
The virus that causes winter vomiting disease invades cells by attaching to particular sugar molecules on the surface of the cells. This is the conclusion of a thesis presented at the Sahlgrenska Academy, University of Gothenburg, Sweden. This result may be an important step in the development of a drug against the regular hospital-based epidemics caused by the virus.
Sexual Health

Z-Cube And Yissum Research Development Company Ltd. Sign A Licensing Agreement

Z-Cube Srl, the corporate venture arm of Zambon Company SpA, and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, announced today that they have entered into a license agreement for Z-Cube to develop and commercialize an innovative nanotechnology drug delivery system for the treatment of pain. The technology was invented by Professor Elka Touitou from the Department of Pharmaceutics, Faculty of Medicine, at the Hebrew University of Jerusalem. Under the terms of the agreement, Z-Cube has received the worldwide exclusive right to develop and commercialize the technology for pain applications and will sponsor a research program to be conducted by Prof. Touitou and her group. Z-Cube has also received the right to grant sublicenses. Yissum will receive license fees, milestones and royalty payments. "We are pleased to partner with Z-Cube, a world leader in the commercialization of drug delivery technologies," said Yaacov Michlin, CEO of Yissum. "Our novel drug delivery system has the potential to enable relief of both mild and severe pain quickly and efficiently." The work of Prof. Touitou, a worldwide authority in the drug delivery field, focuses on the design of novel carriers for enhanced drug absorption and efficiency. Two start-up companies have been established and are active in the development of various novel pharmaceutical products that are based on her previously-developed innovative technologies. "This innovative drug delivery system is a powerful tool enabling the development of improved medicines for the treatment of pain," said Lorenzo Pradella, Ph.D., Business and Operational Development Director of Z-Cube. "Patients suffering from pain will benefit from this new approach that promises to generate upgraded and easier to use therapeutics." In 2007, the worldwide market for pain management products (excluding over-the-counter products) was approximately $ 4.2 billion, representing one of the largest pharmaceutical segments. The expectation is that the demand for prescription pain management products will continue to grow due to favorable demographics, increasing incidence of chronic pain conditions, and heightened awareness of physicians for the need to treat pain. Improved pain treatment includes not only the discovery and marketing of new chemical entities, such as pain killers, but also the development of new delivery systems devoted to reducing side effects, increasing safety and improving compliance. Yissum Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009